



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/724,839	12/01/2003	Gregory Dean Sunvold	P147	2171
27752	7590	07/06/2010		
THE PROCTER & GAMBLE COMPANY			EXAMINER	
Global Legal Department - IP			OLSON, ERIC	
Sycamore Building - 4th Floor				
299 East Sixth Street			ART UNIT	
CINCINNATI, OH 45202			PAPER NUMBER	
			1623	
			MAIL DATE	
			DELIVERY MODE	
			07/06/2010	
			PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/724,839

Applicant(s)

SUNVOLD ET AL.

Examiner

ERIC S. OLSON

Art Unit

1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 May 2010.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 32, 34, 42, 47 and 55 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 32, 34, 42, 47 and 55 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB-06)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on May 17, 2010 has been entered.

Abstract

The abstract of the disclosure is objected to because it contains multiple paragraphs. The abstract should consist of a single paragraph. Correction is required. See MPEP § 608.01(b).

Detailed Action

This office action is a response to applicant's communication submitted May 17, 2010 wherein claim 32 is amended and . This application was filed December 1, 2003 and makes no priority claims.

Claims 32, 34, 42, 47, and 55 are pending in this application.

Claims 32, 34, 42, 47, and 55 as amended are examined on the merits herein.

Applicant's amendment, submitted May 17, 2010, with respect to the rejection of instant claims 32, 34, 42, 47, and 55 under 35 USC 103(a) for being obvious over

Heisey et al. in view of Bui et al., has been fully considered and found to be persuasive to remove the rejection as the claims have been amended to require that the composition comprise at least 35% carbohydrates, said teaching being incompatible with the requirements of Heisey et al. Therefore the rejection is withdrawn.

Applicant's amendment, submitted May 17, 2010, with respect to the rejection of instant claims 32, 34, 42, 47, and 55 under 35 USC 103(a) for being obvious over Anantharaman et al. in view of Kaplan et al., has been fully considered and found to be persuasive to remove the rejection as the claims have been amended to require specific macronutrient concentrations and the presence of beet pulp. Therefore the rejection is withdrawn.

The following new grounds of rejection are introduced:

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation

under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claim 32, 34, 42, 47, and 55 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baillon et al. (US pre-grant publication 2003/0195166, cited in PTO-892, also published as PCT international publication WO01/65949, of record in PTO-1449 submitted May 18, 2005) in view of Kaplan et al. (Reference of record in previous action)

Baillon et al. discloses the use of a non-digestible carbohydrate for the treatment of pathogenic bacteria in the large intestine of a pet animal. (p. 1 paragraph 0012) Non-digestible carbohydrates include fructooligosaccharide such as kestose, nystose, and beta-fructofuranosylnystose, as well as beet pulp. (p. 1 paragraph 0014 - p. 2 paragraph 0016) In a preferred embodiment the non-digestible carbohydrate is a prebiotic which selectively stimulates the growth and/or activity of beneficial bacteria such as bifidobacteria or lactobacilli. (p. 2 paragraphs 0020-0021) The animal treated by this method is preferably a cat or a dog. (p. 2 paragraph 0025) The composition is preferably a cat or dog food such as a kibble (p. 2 paragraph 0026) having 20-30% protein, 10-20% fat, and the remainder (50-70%) being carbohydrate including dietary fiber and ash. (p. 3 paragraph 0028) The oligosaccharide is preferably included at an amount of from 0.1-2%. (p. 3 paragraph 0030) The pet food may be administered as

100% of the diet, meaning that it is nutritionally balanced. (p. 3 paragraph 0036) If it is administered as the sole food source, the composition will necessarily be administered at least once daily. Regarding claims 34 and 47, administering the same composition as the claims to the same subjects will necessarily be expected to produce the same result. Also, regarding "improving physical activity performance," Baillon et al. discloses in p. 2 paragraph 0024 that the claimed compositions can be used to treat *Campylobacter jejuni* infection which can cause diarrhea, tenesmus, vomiting, anorexia, depression, and inflammatory intestinal disease. These conditions would reasonably be expected to reduce the ability of a cat or dog to perform physical activity. Therefore treating *Campylobacter jejuni* infection is reasonably expected to improve a sick animal's ability to perform physical activity. Baillon et al. does not disclose a method comprising administering a composition having the specific claimed ratio of kestose to nystose to fructofuranosyl-nystose.

Kaplan et al. discloses a study of the bacterial fermentation properties of a commercial fructooligosaccharide mixture comprising 32% GF₂ (kestose), 53.6% GF₃ (nystose), and 9.8% GF₄. (fructofuranosyl-nystose). (p. 2682, right column paragraphs 2-3) The fructooligosaccharide mixture was found to support the growth of various beneficial *Lactobacillus* and *Bifidobacterium* species. (p. 2683, left column table 1)

It would have been obvious to one of ordinary skill in the art at the time of the invention to use the commercial fructooligosaccharide mixture studied by Kaplan et al. in the compositions and methods described by Baillon et al. in an amount of 0.2%. One of ordinary skill in the art would have been motivated to use this composition because it

is disclosed by Kaplan et al. to be useful for the desired purpose for which Baillon et al. uses the fructooligosaccharide, namely promoting the growth of beneficial lactic acid bacteria such as *Lactobacilli* and *Bifidobacteria*. One of ordinary skill in the art would reasonably have expected success because substituting one known prior art composition with another that is known to have the same effect is well within the ordinary and routine level of skill in the art.

Therefore the invention taken as a whole is *prima facie* obvious.

Conclusion

No claims are allowed in this application.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERIC S. OLSON whose telephone number is (571)272-9051. The examiner can normally be reached on Monday-Friday, 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia Anna Jiang can be reached on (571)272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Eric S Olson/
Examiner, Art Unit 1623
6/29/2010